Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Gallic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.94 |
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.61 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.48 |
| ▸ | TOP1 known ✓ | P11387 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.94 |
| ▸ | CA1 | P00915 | 4/20 | 0.94 |
| ▸ | CA2 | P00918 | 4/20 | 0.94 |
| ▸ | CA7 | P43166 | 4/20 | 0.94 |
| ▸ | CA9 | Q16790 | 4/20 | 0.94 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.94 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.94 |
| ▸ | MAPT | P10636 | 3/20 | 0.94 |
| ▸ | CA4 | P22748 | 3/20 | 0.94 |
| ▸ | CA6 | P23280 | 3/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | FUT7 | Q11130 | 2/20 | 0.94 |
| ▸ | CA3 | P07451 | 2/20 | 0.94 |
| ▸ | CA5A | P35218 | 2/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gallic Acid SCHEMBL27904848 | 1.00 | CA12 (0.94) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL28613864 | 0.97 | CA12 (0.90) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL5146651 | 0.97 | CA12 (0.90) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL3137007 | 0.97 | CA12 (0.90) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL15012 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL678990 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL1845406 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL30375631 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL4918056 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL8088102 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 510 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070479-A | Ultrasonic indicating device and method for monitoring ultrasonic treatment | JP实验室股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122031352-A | Nanometer compound hirudin protein line for remodelling glycolipid metabolism and preparation method thereof | 山东第一医科大学(山东省医学科学院) | 2026-05-15 | — | — | CN | claimed |
| EP-4582549-A1 | PHENYLACETALDEHYDE PRODUCTION METHOD AND USE APPLICATION THEREOF | Amano Enzyme Inc. (JP) | 2025-07-09 | — | — | EP | claimed |
| WO-2025090061-A1 | ULTRASONIC INDICATOR DEVICE AND METHOD FOR MONITORING ULTRASONICATION | JP LABORATORIES, INC. (US) | 2025-05-01 | — | — | WO | claimed |
| WO-2025075611-A1 | ULTRASONIC INDICATOR BASED ON EMULSION FORMATION | JP LABORATORIES, INC. (US) | 2025-04-10 | — | — | WO | claimed |
| CN-119750505-A | Composite material, preparation method thereof and application of composite material in electrochemical sensor | 长沙半导体技术与应用创新研究院 | 2025-04-04 | — | — | CN | claimed |
| CN-119731331-A | Method for producing phenylacetaldehyde and use thereof | 天野酶制品株式会社 | 2025-03-28 | — | — | CN | claimed |
| CN-116102813-B | Halogen-free flame-retardant resin composition, preparation method thereof and insulated wire | 中化学科学技术研究有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-118217939-A | Modified activated carbon composite material and preparation method and application thereof | 理工清科(重庆)先进材料研究院有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-117717571-A | Phellinus linteus processing method and mulberry Huang Baozhi product | 山东夏津古桑产业研究院有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-110745790-A | Hydrothermal preparation method of bismuth selenide nano powder | 东北大学 | 2020-02-04 | — | — | CN | claimed |
| US-20170165247-A1 | CRYSTALLINE COMPOUNDS OF DABIGATRAN ETEXILATE | OLON S.P.A. (IT) | 2017-06-15 | — | — | US | claimed |
| EP-3169677-A1 | CRYSTALLINE COMPOUNDS OF DABIGATRAN ETEXILATE | OLON S.p.A. (IT) | 2017-05-24 | — | — | EP | claimed |
| WO-2016009405-A1 | CRYSTALLINE COMPOUNDS OF DABIGATRAN ETEXILATE | SIFAVITOR S.R.L. (IT) | 2016-01-21 | — | — | WO | claimed |
| US-20130298933-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND | L'OREAL (FR) | 2013-11-14 | — | — | US | claimed |
| US-20100300472-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND | L'OREAL S.A. (FR) | 2010-12-02 | — | — | US | claimed |
| US-20080081013-A1 | Gallate Single Crystal, Process For Producing The Same, Piezoelectric Device For High-Temperature Use And Piezoelectric Sensor For High-Temperature Use | FUKUDA CRYSTAL LABORATORY (JP) | 2008-04-03 | — | — | US | claimed |
| EP-1877422-A1 | GREEN TEA POLYPHENOL ALPHA SECRETASE ENHANCERS AND METHODS OF USE | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-01-16 | — | — | EP | claimed |
| EP-1867761-A1 | GALLATE SINGLE CRYSTAL, PROCESS FOR PRODUCING THE SAME, PIEZOELECTRIC DEVICE FOR HIGH-TEMPERATURE USE AND PIEZOELECTRIC SENSOR FOR HIGH-TEMPERATURE USE | Fukuda Crystal Laboratory (JP) | 2007-12-19 | — | — | EP | claimed |
| WO-2006116535-A1 | GREEN TEA POLYPHENOL ALPHA SECRETASE ENHANCERS AND METHODS OF USE | UNIVERSITY OF SOUTH FLORIDA (US) | 2006-11-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165247-A1 | CRYSTALLINE COMPOUNDS OF DABIGATRAN ETEXILATE | VKORC1, PROC, F2 | DPP4 87/4885PTGS2 3409/4885EGFR 916/4885 |
| US-20100300472-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND | KRT18, TUBB4A, TUBB4B | DPP4 3439/4885PTGS2 3620/4885EGFR 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.